Mineralys Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $132.0M | $168.6M | $70.4M | $26.2M | — |
| Operating expenses | $170.6M | $192.4M | $84.7M | $31.5M | — |
| Operating income | -$170.6M | -$192.4M | -$84.7M | -$31.5M | — |
| Income tax expense | $0 | $0 | $0 | $0 | — |
| Net income | -$154.7M | -$177.8M | -$71.9M | -$29.8M | — |
| Balance Sheet | |||||
| Cash and equivalents | $172.9M | $114.1M | $49.3M | $87.7M | — |
| Current assets | $661.4M | $205.4M | $249.1M | $112.8M | — |
| Total assets | $661.8M | $205.9M | $251.6M | $114.4M | — |
| Current liabilities | $15.1M | $14.6M | $10.5M | $8.1M | — |
| Stockholders' equity | $646.7M | $191.3M | $241.2M | -$52.3M | -$22.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$142.4M | -$166.3M | -$81.2M | -$29.2M | — |
| Depreciation and amortization | $59,000 | $43,000 | $0 | — | — |
| Stock-based compensation | $19.3M | $11.3M | $5.1M | $455,000 | — |
| Capital expenditure | $15,000 | $96,000 | $0 | — | — |
| Free cash flow | -$142.4M | -$166.4M | -$81.2M | — | — |
Shares outstanding 82.5M · Free float 64.4%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.